XML 60 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Contractual Clinical Trials (Details)
Mar. 14, 2025
USD ($)
Integer
Other Commitments [Line Items]  
Remaining financial contractual commitment | $ $ 264,000
Subsequent Event [Member] | Phase 1b [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer
Estimated Start Date August 2024
Estimated End Date December 2026
Number of Patients in Trial | Integer 37
Expected Date June 2026
Remaining financial contractual commitment | $ [1]
Subsequent Event [Member] | Phase 1b Two [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with doxorubicin in advanced soft tissue sarcoma
Estimated Start Date June 2023
Estimated End Date Recruitment completed September 2024
Expected Date December 2025
Remaining financial contractual commitment | $ $ 264,000
Subsequent Event [Member] | Phase 1b Two [Member] | Minimum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial | Integer 9
Subsequent Event [Member] | Phase 1b Two [Member] | Maximum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial | Integer 18
Subsequent Event [Member] | Randomized Phase 2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description Doxorubicin with or without LB-100 in advanced soft tissue sarcoma
Number of Patients in Trial | Integer 150
Remaining financial contractual commitment | $ [1]
Subsequent Event [Member] | Clinical Trial Phase MD 1b 2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with dostarlimab in ovarian clear cell carcinoma
Estimated Start Date January 2024
Estimated End Date December 2027
Number of Patients in Trial | Integer 21
Expected Date December 2026
Remaining financial contractual commitment | $ [1]
[1] The Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.